Novo Nordisk Faces Generic Pressure as Chile Spends Nearly US$100M a Year on Weight-Loss Drugs

Chileans spend nearly US$100 million a year on weight-loss treatment, according to La Tercera, as seven generic semaglutide applications — including Laboratorio Chile’s Selfix — await regulatory review, putting Novo Nordisk’s retail dominance under direct competitive pressure.

A wide pipe carrying plain discs is partially diverted by a central valve into a second smaller pipe, with faceless silhouettes standing nearby for scale.

DRUG PRICING · GENERIC DRUG ENTRY · SEPTEMBER 28, 2026 · CHILE

At nearly US$100 million a year in spending, according to La Tercera, Chile’s market for weight-loss treatments led by semaglutide has grown large enough to attract a wave of generic challengers — and to put Novo Nordisk’s retail pricing under pressure that the company’s oral pipeline may not fully offset.

According to IQVIA data reported by La Tercera, cumulative semaglutide sales in Chile reached US$415 million at retail prices between July 2021 and July 2026, with 735,952 units sold annually in the most recent 12-month period. Year-on-year sales growth ran at 54% in the year to June 2026, per the same source. In Chile, Novo Nordisk’s injectable glucagon-like peptide-1 (GLP-1) receptor agonists — sold under the Ozempic and Wegovy brands — have operated without generic competition.

That position is now contested. Laboratorio Chile, a subsidiary of Israel’s Teva, has submitted Selfix — a semaglutide generic — for regulatory review at the Instituto de Salud Pública (ISP), Chile’s national medicines regulator, according to La Tercera and Nuevo Poder. Selfix is one of seven generic semaglutide applications under ISP review, according to the regulator. The ISP classifies these generics as chemically synthesised, unlike the biologically derived Ozempic, and says that requires a full review.

The India precedent and what it implies for pricing

The international context sharpens the stakes. In India, where Novo Nordisk’s semaglutide patent expired in March 2026, three manufacturers — Sun Pharma, Dr. Reddy’s and Glenmark — received approval from the Drug Controller General of India (DCGI), India’s medicines regulator, and began selling generic versions within days of the patent lapse, according to Cinco Días. Dr. Reddy’s launched Obeda at approximately 4,200 rupees (around 39 euros) per month; Glenmark’s Glipiq was priced between 325 and 440 rupees per week, per Cinco Días. By comparison, the list price for Ozempic in the United States for an uninsured patient runs between US$900 and US$1,100 per month, according to Cinco Días. Cinco Días reported that the Indian generic entry is expected to reduce treatment costs by up to 80%.

Chile’s patent and regulatory environment differs from India’s, and the ISP said in August that all seven applications would go in September before its new-products commission, which proposes approval or rejection; as of 19 September, La Tercera reported Laboratorio Chile was still awaiting approval for Selfix. The India case is therefore an international reference point, not a direct forecast — but it establishes that rapid multi-entrant generic competition in semaglutide markets can compress prices sharply once regulatory clearance is granted.

Domenico Forte, chief executive of Novo Nordisk in Chile, told La Tercera the evaluation of the Wegovy launch ‘is positive’ and that Chile is among the first countries in the region to have the drug. The company’s broader posture in 2026 has been to compete on volume and oral formulations: Novo Nordisk’s chief executive Mike Doustdar stated in the company’s May 2026 first-quarter results announcement that ‘the strong Wegovy performance, combined with continued growth in International Operations, has led us to raise our 2026 guidance for both adjusted sales and adjusted operating profit’ — and on 4 August 2026 the company raised its guidance again, to adjusted sales growth of 0% to -6% at constant exchange rates.

A market the public system does not yet cover

The Chilean government’s Garantías Explícitas en Salud (GES) programme — the statutory benefit package that covers 90 health conditions under the Decreto GES 2025-2028 announced by President Gabriel Boric and Health Minister Ximena Aguilera in December 2025 — does not list obesity among its guaranteed conditions. The DESAL (Departamento de Economía de la Salud, Chile’s Ministry of Health health-economics unit) analysis of the Ley N°21.198 (Ley Cenabast) — which allows the Central de Abastecimiento del Sistema Nacional de Servicios de Salud (Cenabast), Chile’s public procurement agency, to intermediate drug purchases for private pharmacies — covers the 2021–2024 period and evaluates price and savings impacts across the Cenabast portfolio.

Laboratorio Chile general manager Juan Meli told La Tercera that there is currently no broad coverage for this type of treatment. A DESAL report published in December 2021 noted that Chile’s pharmaceutical market represented 1.6% of gross domestic product (GDP) in 2020, with average annual growth of 10% between 2011 and 2020.

The principal friction in the generic entry scenario is regulatory throughput, not commercial intent. ISP review timelines for new generic applications vary, and a cleared registration does not translate immediately into stocked pharmacy shelves or procurement-list inclusion. With seven applications already under review, Chile could see multi-entrant competition once the first synthetic semaglutide is cleared; the ISP said in May that the remaining applications would then advance expeditiously.

Analyst estimates for the global obesity-drug market were revised downward in early 2026. Jefferies cut its 2030 weight-loss market projection by 20% to a maximum of US$80 billion, from a 2023 estimate of more than US$100 billion, according to Reuters; Jefferies analyst Michael Leuchten told Reuters: ‘That $150 billion pie is gone, even if you’re very bullish on volumes.’ These revisions reflect the combined effect of price competition in the United States and the accelerating generic entry in markets where patents have lapsed.

What to Watch

  1. ISP regulatory decision on Selfix (Laboratorio Chile / Teva): the timing and outcome will determine when a lower-priced semaglutide reaches Chilean pharmacies.
  2. How many of the seven semaglutide generic applications under ISP review are approved, and in what order.
  3. Any Cenabast intermediation decision covering semaglutide, which would extend price pressure into the public-adjacent retail channel and expand access beyond current out-of-pocket payers.
THE HEALTHSIGNALS BRIEF
A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.
Step 1 of 2 · Free. Work email for instant access. Unsubscribe anytime. By subscribing you agree to receive The HealthSignals Brief by email and accept our Privacy Policy.

The deeper structural point is that Chile’s semaglutide market has grown large enough — US$415 million cumulatively, nearly US$100 million a year by La Tercera’s estimate — to make generic entry commercially viable, independent of what happens in Europe, where Cinco Días reports semaglutide patent protection runs until 2031. The competitive clock in Chile is set by the ISP’s review calendar, not by Novo Nordisk’s global patent strategy.

Chile Semaglutide Market in Numbers

US$415M

Cumulative semaglutide sales at retail prices, July 2021 – July 2026

IQVIA, via La Tercera

735,952

Units sold in the moving annual total (MAT) to 2026

IQVIA, via La Tercera

+54%

Sales growth, July 2025 – June 2026

IQVIA, via La Tercera

7

Generic semaglutide applications under ISP review

Instituto de Salud Pública (ISP)

Sources: La Tercera (IQVIA data), September 2026; Instituto de Salud Pública (ISP), August 2026.

Why this is relevant

Patients

Obesity is not among the 90 GES guaranteed conditions, and Laboratorio Chile says there is currently no broad coverage for this type of treatment; ISP approval of generic semaglutide, including Selfix, could reduce treatment costs, though the timeline for regulatory clearance and pharmacy availability remains uncertain.

Industry

Seven chemically synthesised semaglutide applications are before the ISP, including Selfix from Teva subsidiary Laboratorio Chile, at a moment when cumulative semaglutide sales have reached US$415 million and year-on-year growth stands at 54%, making the market commercially significant enough to sustain competitive entry and potential price compression.

Payers

Obesity is not a GES guaranteed condition; Laboratorio Chile estimates that a generic costing US$1,283 a year, against US$3,206 for the brand, could save the health system US$225 million — a company projection that assumes ISP approval.

Caregivers

With Ozempic retailing at between 165,000 and more than 300,000 Chilean pesos per pen, according to La Tercera, families supporting members with obesity face sustained financial pressure until generic entry, if approved by the ISP, translates into lower pharmacy shelf prices — a lag that depends on ISP throughput and pharmacy uptake.

Sources: Novo Nordisk: 2026 outlook raised, 4 August 2026 · Emol: ISP y la próxima aprobación de semaglutida genérica · Reuters: Obesity market sales potential · Colmena: Los 90 problemas de salud GES · La Tercera: Casi US$100 millones por año: el gasto de los chilenos para adelgazar y el boom de Ozempic · La Tercera: Laboratorio Chile estima en US$225 millones el ahorro del Fisco con venta del homólogo genérico del Ozempic · La Tercera: Laboratorio Chile anuncia que homólogo genérico de Ozempic costará menos de la mitad del precio · Nuevo Poder: Laboratorio Chile estima ahorro fiscal de US$225 mills. si ISP autoriza semaglutida genérica · SOCHOB: Instituto de Salud Pública de Chile informa sobre semaglutida · Ministerio de Salud Chile / DESAL: Análisis económico de los medicamentos incluidos en la Ley Cenabast · Ministerio de Salud Chile / DESAL: Informe de medicamentos, diciembre 2021 · Ministerio de Salud Chile: Chile garantiza 90 problemas de salud con inversión récord de $100 mil millones anuales · Cinco Días: La India comienza a vender Ozempic hasta un 80% más barato tras la liberalización de la patente de Novo Nordisk · Novo Nordisk: Q1 2026 company announcement · Cinco Días: Novo Nordisk eleva sus previsiones para 2026 por el éxito de Wegovy · Cinco Días: Novo Nordisk y Eli Lilly entran en una nueva era con sus pastillas para adelgazar

THE HEALTHSIGNALS BRIEF

A fortnightly PDF compiling our analysis on pharma, medical devices, health policy and epidemiology across Latin America and the United States.

Built for pharma, market-access, regulatory, policy and investor teams, with the main findings of our gated reports included.

Your subscription could not be validated.
You have successfully subscribed.

Comments

Related